Full Year 2024 Fresenius Medical Care AG Earnings Call Transcript

Feb 25, 2025 / 01:00PM GMT

Release Date Price: €43.93

Transcript

Key Points

Positve

Fresenius Medical Care AG (FMS) achieved a significant improvement in operating income, with a 31% growth in the fourth quarter, driven by both care delivery and care enablement segments.
The company raised its total savings target from EUR650 million to EUR750 million by the end of 2025, due to the momentum in the FME25 transformation program.
Fresenius Medical Care AG (FMS) plans to propose a dividend increase of 21%, reflecting a strong commitment to shareholder returns.
The company reported a strong net promoter score of 72, indicating high patient satisfaction with the quality of its services.
Fresenius Medical Care AG (FMS) achieved 4% organic growth and reached the upper end of its earnings outlook for 2024, demonstrating effective execution of its strategic plan.

Negative

The company continues to experience elevated mortality rates in the United States, which impacts overall treatment volumes.
Fresenius Medical Care AG (FMS) faced a 1.6% revenue headwind from divestments in 2024, affecting overall revenue growth.
The value-based care business contributed negatively to the bottom line, with a negative EBIT contribution of EUR20 million to EUR40 million.
The company anticipates a net labor headwind of EUR150 million to EUR200 million in 2025, primarily due to wage inflation.
Fresenius Medical Care AG (FMS) expects a 1% revenue headwind in 2025 from the successful execution of its portfolio optimization plan, which includes divestitures.

Operator

Ladies and gentlemen, welcome to the Fresenius Medical Care report on the fourth-quarter 2024 conference call. I'm Sandra, the Chorus Call operator. I would like to remind you that all participants have been listening more than the conference is being recorded.

This recording will also be available on the Fresenius Medical Care website. Additionally, the transcript of this conference will also be published on the website of the conference. (Operator Instructions) The presentation will be followed by a Q&A session. You can register for questions at any time by pressing and one in your telephone.

The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Dominik Heger. Please go ahead, sir.

Dominik Heger

Fresenius Medical Care AG - Head of Investor Relations, Strategic Development & Communications, EVP

Thank you, Sandra. I would like to welcome everyone to our earnings call for the fourth quarter and financial year 2024. Thank you for joining us today. As always, I start out the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.